Literature DB >> 11684089

TNFalpha-induced glutathione depletion lies downstream of cPLA(2) in L929 cells.

H L Hayter1, B J Pettus, F Ito, L M Obeid, Y A Hannun.   

Abstract

Both glutathione (GSH) depletion and arachidonic acid (AA) generation have been shown to regulate sphingomyelin (SM) hydrolysis and are known components in tumor necrosis factor alpha (TNFalpha)-induced cell death. In addition, both have hypothesized direct roles in activation of N-sphingomyelinase (SMase); however, it is not known whether these are independent pathways of N-SMase regulation or linked components of a single ordered pathway. This study was aimed at differentiating these possibilities using L929 cells. Depletion of GSH with L-buthionin-(S,R)-sulfoximine (BSO) induced 50% hydrolysis of SM at 12 h. In addition, TNF induced a depletion of GSH, and exogenous addition of GSH blocked TNF-induced SM hydrolysis as well as TNF-induced cell death. Together, these results establish GSH upstream of SM hydrolysis and ceramide generation in L929 cells. We next analyzed the L929 variant, C12, which lacks both cytosolic phospholipase A(2) (cPLA(2)) mRNA and protein, in order to determine the relationship of cPLA(2) and GSH. TNF did not induce a significant drop in GSH levels in the C12 line. On the other hand, AA alone was capable of inducing a 60% depletion of GSH in C12 cells, suggesting that these cells remain responsive to AA distal to the site of cPLA(2). Furthermore, depleting GSH with BSO failed to effect AA release, but caused a drop in SM levels, showing that the defect in these cells was upstream of the GSH drop and SMase activation. When cPLA(2) was restored to the C12 line by expression of the cDNA, the resulting CPL4 cells regained sensitivity to TNF. Treatment of the CPL4 cells with TNF resulted in GSH levels dropping to levels near those of the wild-type L929 cells. These results demonstrate that GSH depletion following TNF treatment in L929 cells is dependent on intact cPLA(2) activity, and suggest a pathway in which activation of cPLA(2) is required for the oxidation and reduction of GSH levels followed by activation of SMases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684089     DOI: 10.1016/s0014-5793(01)02967-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function.

Authors:  Iyad Sultan; Can E Senkal; Suriyan Ponnusamy; Jacek Bielawski; Zdzislaw Szulc; Alicja Bielawska; Yusuf A Hannun; Besim Ogretmen
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

2.  Lactosylceramide interacts with and activates cytosolic phospholipase A2α.

Authors:  Hiroyuki Nakamura; Yuta Moriyama; Tomohiko Makiyama; Shunsuke Emori; Hisahiro Yamashita; Risa Yamazaki; Toshihiko Murayama
Journal:  J Biol Chem       Date:  2013-06-25       Impact factor: 5.157

3.  Evidence of contribution of iPLA2β-mediated events during islet β-cell apoptosis due to proinflammatory cytokines suggests a role for iPLA2β in T1D development.

Authors:  Xiaoyong Lei; Robert N Bone; Tomader Ali; Sheng Zhang; Alan Bohrer; Hubert M Tse; Keshore R Bidasee; Sasanka Ramanadham
Journal:  Endocrinology       Date:  2014-07-08       Impact factor: 4.736

4.  TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice.

Authors:  Robert Stöhr; Ben Arpad Kappel; Daniela Carnevale; Michele Cavalera; Maria Mavilio; Ivan Arisi; Valentina Fardella; Giuseppe Cifelli; Viviana Casagrande; Stefano Rizza; Antonino Cattaneo; Alessandro Mauriello; Rossella Menghini; Giuseppe Lembo; Massimo Federici
Journal:  Mol Metab       Date:  2015-08-06       Impact factor: 7.422

Review 5.  The Sources of Reactive Oxygen Species and Its Possible Role in the Pathogenesis of Parkinson's Disease.

Authors:  Minrui Weng; Xiaoji Xie; Chao Liu; Kah-Leong Lim; Cheng-Wu Zhang; Lin Li
Journal:  Parkinsons Dis       Date:  2018-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.